Pura Vida Investments is a healthcare-focused investment vehicle specialized in private equity investments.
Pura Vida Investments is a fundamentally driven, market neutral healthcare-focused investment vehicle. The objective of the firm is to identify and capitalize on structural changes in the healthcare landscape and on inflections in company specific valuations. The firm strives to look past day-to-day volatility and to hone in on major value shifts over the medium to longer term.The firm’s portfolio is managed by Efrem Kamen and Doron Junger MD and is run in a market neutral fashion, investing across most areas of healthcare, including medical devices, biotechnology, pharmaceuticals, tools, life sciences and healthcare services. The Fund has an optional 10% allocation to designated investments, allowing participation in private and certain illiquid public securities, which is managed by Frank Litvack MD.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Feb 3, 2022
Greenlight Biosciences
|
Post-IPO Equity | $125.50M | Agriculture | — |
Jan 25, 2022
Metagenomi
|
Series B | $175M | Artificial Intelligence | — |
Dec 7, 2021
Freenome
|
Series D | $300M | Biotechnology | — |
Oct 7, 2021
Science 37
|
Post-IPO Equity | $200M | Biotechnology | — |
May 11, 2021
Caris Life Sciences
|
Private Equity(PE) | $830M | Biotechnology | — |